Real-world long-term effectiveness of ustekinumab in ulcerative colitis: results from a spanish open-label cohort

References

• Ungaro R, Mehandru S, Allen PB, et al. Ulcerative colitis. Lancet. 2017;389(10080):1756–1770. doi: 10.1016/S0140-6736(16)32126-2.
   PubMed Web of Science ®Google Scholar
• Turner D, Ricciuto A, Lewis A, et al. STRIDE-II: an update on the selecting therapeutic targets in inflammatory bowel disease (STRIDE) initiative of the international organization for the study of IBD (IOIBD): determining therapeutic goals for treat-to-Target strategies in IBD. Gastroenterology. 2021;160(5):1570–1583. doi: 10.1053/j.gastro.2020.12.031.
   PubMed Web of Science ®Google Scholar
• Wyant T, Yang L, Fedyk E. In vitro assessment of the effects of vedolizumab binding on peripheral blood lymphocytes. MAbs. 2013;5(6):842–850. doi: 10.4161/mabs.26392.
   PubMed Web of Science ®Google Scholar
• Stelara Summary of Product Characteristics. [cited 2023 Jun 20]. https://www.ema.europa.eu/en/documents/product-information/stelara-epar-product-information_en.pdf.
   Google Scholar
• Bermejo F, Jimenez L, Algaba A, et al. Re-induction with intravenous ustekinumab in patients with Crohn’s disease and a loss of response to this therapy. Inflamm Bowel Dis. 2022;28(1):41–47. doi: 10.1093/ibd/izab015.
   PubMed Web of Science ®Google Scholar
• Danese S, Afif W, Abreu M, et al. OP15 efficacy of ustekinumab for ulcerative colitis through 4 years: final clinical and endoscopy outcomes from the UNIFI long-term extension. J Crohn’s Colitis. 2023;17(Supplement_1):i19–i20. doi: 10.1093/ecco-jcc/jjac190.0015.
   Google Scholar
• Amiot A, Filippi J, Abitbol V, et al. Effectiveness and safety of ustekinumab induction therapy for 103 patients with ulcerative colitis: a GETAID multicentre real-world cohort study. Aliment Pharmacol Ther. 2020;51(11):1039–1046. doi: 10.1111/apt.15717.
   PubMed Web of Science ®Google Scholar
• Chaparro M, Garre A, Iborra M, et al. Effectiveness and safety of ustekinumab in ulcerative colitis: real-world evidence from the ENEIDA registry. J Crohns Colitis. 2021;15(11):1846–1851. doi: 10.1093/ecco-jcc/jjab070.
   PubMed Web of Science ®Google Scholar
• Fumery M, Filippi J, Abitbol V, et al. Effectiveness and safety of ustekinumab maintenance therapy in 103 patients with ulcerative colitis: a GETAID cohort study. Aliment Pharmacol Ther. 2021;54(7):944–951. doi: 10.1111/apt.16544.
   PubMed Web of Science ®Google Scholar
• Chiappetta MF, Viola A, Mastronardi M, et al. One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy. Expert Opin Biol Ther. 2021;21(11):1483–1489. doi: 10.1080/14712598.2021.1981855.
   PubMed Web of Science ®Google Scholar
• Pugliese D, Privitera G, Fiorani M, et al. Targeting IL12/23 in ulcerative colitis: update on the role of ustekinumab. Therap Adv Gastroenterol. 2022;15:17562848221102283. doi: 10.1177/17562848221102283.
   Web of Science ®Google Scholar
• Dalal RS, Esckilsen S, Barnes EL, et al. Predictors and outcomes of ustekinumab dose intensification in ulcerative colitis: a multicenter cohort study. Clin Gastroenterol Hepatol. 2022;20(10):2399–2401.e4. doi: 10.1016/j.cgh.2021.03.028.
   PubMed Web of Science ®Google Scholar
• Magro F, Gionchetti P, Eliakim R, et al. Third european evidence-based consensus on diagnosis and management of ulcerative colitis. Part 1: definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohns Colitis. 2017;11(6):649–670. doi: 10.1093/ecco-jcc/jjx008.
   PubMed Web of Science ®Google Scholar
• Sands BE, Sandborn WJ, Panaccione R, et al. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med. 2019;381(13):1201–1214. doi: 10.1056/NEJMoa1900750.
   PubMed Web of Science ®Google Scholar
• Dulai PS, Singh S, Jairath V, et al. Prevalence of endoscopic improvement and remission according to patient-reported outcomes in ulcerative colitis. Aliment Pharmacol Ther. 2020;51(4):435–445. doi: 10.1111/apt.15577.
   PubMed Web of Science ®Google Scholar
• Narula N, Alshahrani AA, Yuan Y, et al. Patient-Reported outcomes and endoscopic appearance of ulcerative colitis: a systematic review and meta-analysis. Clin Gastroenterol Hepatol. 2019;17(3):411–418.e3. doi: 10.1016/j.cgh.2018.06.015.
   PubMed Web of Science ®Google Scholar
• Ochsenkuhn T, Tillack C, Szokodi D, et al. Clinical outcomes with ustekinumab as rescue treatment in therapy-refractory or therapy-intolerant ulcerative colitis. United European Gastroenterol J. 2020;8(1):91–98. doi: 10.1177/2050640619895361.
   PubMed Web of Science ®Google Scholar
• Hong SJ, Krugliak Cleveland N, et al. Real-world effectiveness and safety of ustekinumab for ulcerative colitis from 2 tertiary IBD centers in the United States. Crohn’s Colitis. 2021;3(1):otab002.
   Web of Science ®Google Scholar
• Meyer A, Fumery M, Peyrin-Biroulet L, et al. Comparative real-world effectiveness of vedolizumab and ustekinumab for patients with ulcerative colitis: a GETAID multicentre cohort study. Scand J Gastroenterol. 2022;57(12):1454–1462. doi: 10.1080/00365521.2022.2095668.
   PubMed Web of Science ®Google Scholar
• Honap S, Al-Hillawi L, Baillie S, et al. Ustekinumab for the treatment of moderate to severe ulcerative colitis: a multicentre UK cohort study. Frontline Gastroenterol. 2022;13(6):517–523. doi: 10.1136/flgastro-2022-102168.
   PubMed Web of Science ®Google Scholar
• Thunberg J, Bjorkqvist O, Hedin CRH, et al. Ustekinumab treatment in ulcerative colitis: real-world data from the swedish inflammatory bowel disease quality register. United European Gastroenterol J. 2022;10(7):631–639. doi: 10.1002/ueg2.12275.
   PubMed Web of Science ®Google Scholar
• Ha C, Ullman TA, Siegel CA, et al. Patients enrolled in randomized controlled trials do not represent the inflammatory bowel disease patient population. Clin Gastroenterol Hepatol. 2012;10(9):1002–1007; quiz e78. doi: 10.1016/j.cgh.2012.02.004.
   PubMed Web of Science ®Google Scholar
• Taxonera C, Olivares D, Lopez-Garcia ON, et al. Meta-analysis: real-world effectiveness and safety of ustekinumab in patients with ulcerative colitis. Aliment Pharmacol Ther. 2023;57(6):610–619. doi: 10.1111/apt.17386.
   PubMed Web of Science ®Google Scholar
• Gisbert JP, Parody-Rúa E, Chaparro M. Efficacy, effectiveness, and safety of ustekinumab for the treatment of ulcerative colitis: a systematic review. Inflamm Bowel Dis. 2023;XX:izac275. doi: 10.1093/ibd/izac275.
   Web of Science ®Google Scholar
• Abreu MT, Rowbotham DS, Danese S, et al. Efficacy and safety of maintenance ustekinumab for ulcerative colitis through 3 years: UNIFI long-term extension. J Crohns Colitis. 2022;16(8):1222–1234. doi: 10.1093/ecco-jcc/jjac030.
   PubMed Web of Science ®Google Scholar
• Danese S, Sands BE, Abreu MT, et al. Early symptomatic improvement after ustekinumab therapy in patients with ulcerative colitis: 16-Week data from the UNIFI trial. Clin Gastroenterol Hepatol. 2022;20(12):2858–2867.e5. doi: 10.1016/j.cgh.2022.02.050.
   PubMed Web of Science ®Google Scholar
• Bermejo F, Algaba A, Bonillo D, et al. Limitations of the determination of faecal calprotectin in patients with ulcerative colitis and inflammatory polyps. Gastroenterol Hepatol. 2020;43(2):73–78. J doi: 10.1016/j.gastrohep.2019.08.003.
   PubMed Web of Science ®Google Scholar
• Alsoud D, De Hertogh G, Compernolle G, et al. Real-world endoscopic and histological outcomes are correlated with ustekinumab exposure in patients with ulcerative colitis. J Crohns Colitis. 2022;16(10):1562–1570. doi: 10.1093/ecco-jcc/jjac067.
   PubMed Web of Science ®Google Scholar
• Sandborn WJ, Feagan BG, Danese S, et al. Safety of ustekinumab in inflammatory bowel disease: pooled safety analysis of results from phase 2/3 studies. Inflamm Bowel Dis. 2021;27(7):994–1007. doi: 10.1093/ibd/izaa236.
   PubMed Web of Science ®Google Scholar
• Ten Bokkel Huinink S, Biemans V, Duijvestein M, et al. Re-induction with intravenous ustekinumab after secondary loss of response is a valid optimization strategy in Crohn’s disease. Eur J Gastroenterol Hepatol. 2021;33(1S Suppl 1):e783–e788. doi: 10.1097/MEG.0000000000002256.
   PubMed Web of Science ®Google Scholar
• Perez Valle I, Varela Trastoy P, Mancebo Mata A. Preliminary experience of maintenance treatment with intravenous ustekinumab as a rescue treatment for loss of response to subcutaneous doses. Rev Esp Enferm Dig. 2021;113(3):186–188.
   PubMed Web of Science ®Google Scholar
• Kopylov U, Hanzel J, Liefferinckx C, et al. Effectiveness of ustekinumab dose escalation in Crohn’s disease patients with insufficient response to standard-dose subcutaneous maintenance therapy. Aliment Pharmacol Ther. 2020;52(1):135–142. doi: 10.1111/apt.15784.
   PubMed Web of Science ®Google Scholar
• O’Donnell S, Stempak JM, Steinhart AH, et al. Higher rates of dose optimisation for infliximab responders in ulcerative colitis than in Crohn’s disease. J Crohns Colitis. 2015;9(10):830–836. doi: 10.1093/ecco-jcc/jjv115.
   PubMed Web of Science ®Google Scholar
• Bastida G, Marin-Jimenez I, Fores A, et al. Treatment patterns and intensification within 5 year of follow-up of the first-line anti-TNFalpha used for the treatment of IBD: results from the VERNE study. Dig Liver Dis. 2022;54(1):76–83. doi: 10.1016/j.dld.2021.06.005.
   PubMedGoogle Scholar
• Olivera P, Thiriet L, Luc A, et al. Treatment persistence for infliximab versus adalimumab in Crohn’s disease: a 14-year single-center experience. Inflamm Bowel Dis. 2017;23(6):976–985. doi: 10.1097/MIB.0000000000001072.
   PubMed Web of Science ®Google Scholar
• Adedokun OJ, Xu Z, Marano C, et al. Ustekinumab pharmacokinetics and exposure response in a phase 3 randomized trial of patients with ulcerative colitis. Clin Gastroenterol Hepatol. 2020;18(10):2244–2255 e9. doi: 10.1016/j.cgh.2019.11.059.
   PubMed Web of Science ®Google Scholar
• Gutierrez A, Rodriguez-Lago I. How to optimize treatment with ustekinumab in inflammatory bowel disease: lessons learned from clinical trials and real-world data. Front Med. 2021;8:640813. doi: 10.3389/fmed.2021.640813.
   Web of Science ®Google Scholar
• Shmais M, Regueiro M, Hashash JG. Proactive versus reactive therapeutic drug monitoring: why, when, and how? Inflamm Intest Dis. 2022;7(1):50–58. doi: 10.1159/000518755.
   PubMedGoogle Scholar
• Gisbert JP, Garcia MJ, Chaparro M. Rescue therapies for steroid-refractory acute severe ulcerative colitis: a review. J Crohns Colitis. 2023;17(6):972–994. doi: 10.1093/ecco-jcc/jjad004.
   PubMed Web of Science ®Google Scholar
• Aoki Y, Sujino T, Kawaguchi T, et al. Effectiveness and durability of ustekinumab therapy with or without immunomodulators for ulcerative colitis patients in Japan. Crohns Colitis 360. 2022;4(2):otac010. doi: 10.1093/crocol/otac010.
   PubMedGoogle Scholar